(Albany, US) DelveInsight has launched a new report on Acute on Chronic Liver Failure Epidemiology
DelveInsight’s ‘Acute On Chronic Liver Failure (ACLF) – Epidemiology Forecast to 2030′ report delivers an in-depth understanding of the disease, historical and forecasted Acute On Chronic Liver Failure (ACLF) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
The term Acute-on-Chronic Liver Failure (ACLF) was first introduced in 1995 to describe a condition in which two “lesions” or “insults” act simultaneously on the liver, one of which is chronic and the other is acute. However, the universally accepted and used definition of ACLF is still lacking. Thus, several definitions have been developed by expert groups from the American Association for the Study of Liver Diseases (AASLD), European Association for the Study of the Liver (EASL), and Asian-Pacific Association for the Study of the Liver (APASL). According to AASLD and EASL working group ACLF is, “Acute deterioration of pre-existing chronic liver disease usually related to a precipitating event and associated with increased mortality at 3-months due to multi-system organ failure”. On the other hand, the group of experts from APASL define the ACLF as, “Acute liver injury manifesting as jaundice (serum bilirubin ≥5 mg/dL) and coagulopathy (INR ≥1.5 or prothrombin activity of <40%), complicated within 4 weeks by ascites and/or encephalopathy in a patient previously diagnosed or undiagnosed chronic liver diseases.”
Click here for Free sample page:- https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-epidemiology-forecast
Acute on Chronic Liver Failure Epidemiology
Organ failure is a major factor in the clinical course of ACLF. Moreover, the presence of hepatic encephalopathy (HE) within 4 weeks is part of the criteria for defining ACLF. It can be due to hepatotropic or non-hepatotropic agents/causes. Major etiologic agents responsible for precipitating ACLF are Hepatotropic viral infections, such as Hepatitis B virus, infection and super-infection with HEV, etc., and Non-hepatotropic insults, like surgery, trauma, and viral infections if producing direct hepatic insult could lead to ACLF.
Key facts of the report
Acute on Chronic Liver Failure Report Scope
Download free sample page:- https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-epidemiology-forecast
Table of content
1. Key Insights
2. Executive Summary of Acute On Chronic Liver Failure (ACLF)
3. Competitive Intelligence Analysis for Acute On Chronic Liver Failure (ACLF)
4. Acute On Chronic Liver Failure (ACLF): Market Overview at a Glance
5. Acute On Chronic Liver Failure (ACLF): Disease Background and Overview
6. Patient Journey
7. Acute On Chronic Liver Failure (ACLF) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Acute On Chronic Liver Failure (ACLF) Treatment
11. Marketed Products
12. Emerging Therapies
13. Acute On Chronic Liver Failure (ACLF): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Acute On Chronic Liver Failure (ACLF)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Why should you buy this report?
Related Reports
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/